Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
370 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2015', provides an overview of the Congestive Heart Failure (Heart Failure)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Congestive Heart Failure (Heart Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Congestive Heart Failure (Heart Failure) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Congestive Heart Failure (Heart Failure) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Congestive Heart Failure (Heart Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Congestive Heart Failure (Heart Failure) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Congestive Heart Failure (Heart Failure) Overview 11 Therapeutics Development 12 Pipeline Products for Congestive Heart Failure (Heart Failure) - Overview 12 Pipeline Products for Congestive Heart Failure (Heart Failure) - Comparative Analysis 13 Congestive Heart Failure (Heart Failure) - Therapeutics under Development by Companies 14 Congestive Heart Failure (Heart Failure) - Therapeutics under Investigation by Universities/Institutes 20 Congestive Heart Failure (Heart Failure) - Pipeline Products Glance 22 Late Stage Products 22 Clinical Stage Products 23 Early Stage Products 24 Congestive Heart Failure (Heart Failure) - Products under Development by Companies 25 Congestive Heart Failure (Heart Failure) - Products under Investigation by Universities/Institutes 32 Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development 34 Acorda Therapeutics, Inc. 34 Amgen Inc. 35 Anexon, Inc. 36 AnGes MG, Inc. 37 Angion Biomedica Corp. 38 ARCA biopharma, Inc. 39 Ascelegen Therapeutics, Inc. 40 Asklepios BioPharmaceutical, Inc. 41 Athersys, Inc. 42 Bayer AG 43 BEAT BioTherapeutics Corp. 44 Bial - Portela & Ca, S.A. 45 Bioheart, Inc. 46 BioLineRx, Ltd. 47 Bristol-Myers Squibb Company 48 Cardio3 BioSciences SA 49 Cardioxyl Pharmaceuticals, Inc. 50 Celladon Corporation 51 Cellmid Limited 52 FibroGen, Inc. 53 GlaxoSmithKline plc 54 Glucox Biotech AB 55 Innopharmax Inc. 56 Jiangsu Hengrui Medicine Co., Ltd. 57 Juventas Therapeutics, Inc. 58 Laboratoires Pierre Fabre SA 59 Lead Pharma Holding B.V. 60 Lee's Pharmaceutical Holdings Limited 61 Les Laboratoires Servier SAS 62 Lonestar Heart, Inc. 63 Mast Therapeutics, Inc. 64 Merck & Co., Inc. 65 Mesoblast Limited 66 Mezzion Pharma Co. Ltd. 67 MI.TO. Technology S.r.L. 68 miRagen Therapeutics, Inc. 69 NeoStem, Inc. 70 Novartis AG 71 Nyken BV 72 Ono Pharmaceutical Co., Ltd. 73 Palatin Technologies, Inc. 74 Pfizer Inc. 75 PharmaIN Corporation 76 PhaseBio Pharmaceuticals, Inc. 77 Pluristem Therapeutics Inc. 78 QUANTUM GENOMICS Corp. 79 Recardio GmbH 80 RedHill Biopharma Ltd. 81 RegenoCELL Therapeutics, Inc. 82 Sanofi 83 Stemedica Cell Technologies, Inc. 84 Target Heart Biotec Srl 85 Torrent Pharmaceuticals Limited 86 Trevena, Inc. 87 uniQure N.V. 88 Vicore Pharma AB 89 Zensun (Shanghai) Sci & Tech Co., Ltd. 90 Congestive Heart Failure (Heart Failure) - Therapeutics Assessment 91 Assessment by Monotherapy Products 91 Assessment by Combination Products 92 Assessment by Target 93 Assessment by Mechanism of Action 97 Assessment by Route of Administration 101 Assessment by Molecule Type 103 Drug Profiles 105 (sacubitril + valsartan) - Drug Profile 105 AdipoCell - Drug Profile 107 AdipoCell + MyoCell - Drug Profile 109 aladorian - Drug Profile 110 aliskiren fumarate - Drug Profile 112 AMR-001 - Drug Profile 114 ANG-3557 - Drug Profile 116 ANG-4011 - Drug Profile 117 AntimiR-199a - Drug Profile 118 ANX-042 - Drug Profile 119 ARX-720 - Drug Profile 120 BAY-1067197 - Drug Profile 121 BAY-1142524 - Drug Profile 122 BBR-12 - Drug Profile 123 beperminogene perplasmid - Drug Profile 124 BIA-51058 - Drug Profile 129 BNP-CHF - Drug Profile 130 BR-5489 - Drug Profile 131 bucindolol hydrochloride - Drug Profile 132 C-21 - Drug Profile 134 C3BSCQR-1 - Drug Profile 136 CAP-1002 - Drug Profile 138 CARD-024 - Drug Profile 140 carvedilol CR - Drug Profile 142 carvedilol CR - Drug Profile 143 carvedilol phosphate ER - Drug Profile 144 cenderitide - Drug Profile 145 CGEN-856 - Drug Profile 147 cimaglermin alfa - Drug Profile 149 CM-1 - Drug Profile 151 CMK-103 - Drug Profile 153 CTX-101 - Drug Profile 154 CTX-201 - Drug Profile 155 CXL-1036 - Drug Profile 156 CXL-1427 - Drug Profile 157 Drug for Heart Failure - Drug Profile 158 Drug to Inhibit Calpain for Heart Failure - Drug Profile 159 Drugs to Inhibit miR-425 for Hypertension and Heart Failure - Drug Profile 160 F-373280 - Drug Profile 161 FG-6874 - Drug Profile 162 FG-8205 - Drug Profile 163 finerenone - Drug Profile 164 Gene Therapy for Congestive Heart Failure - Drug Profile 165 Gene Therapy for Ischemic Heart Failure - Drug Profile 166 Gene Therapy to Activate AC-6 for Congestive Heart Failure - Drug Profile 167 Gene Therapy to Activate S100-A1 for Congestive Heart Failure - Drug Profile 168 Gene Therapy to Activate S100-A1 for Heart Failure - Drug Profile 169 Gene Therapy to Activate UCn 2 for Congestive Heart Failure - Drug Profile 170 Gene Therapy to Inhibit GRK2 for Heart Failure - Drug Profile 171 Gene Therapy to Inhibit Mef2 for Heart Failure - Drug Profile 172 GSK-2798745 - Drug Profile 173 GSK-2881078 - Drug Profile 174 istaroxime - Drug Profile 175 ITD-1 - Drug Profile 177 ivabradine - Drug Profile 178 ivabradine SR - Drug Profile 180 JVS-100 - Drug Profile 181 Mesenchymal Stem Cells - Drug Profile 183 MGN-9103 - Drug Profile 185 MicroRNAs for Heart Failure - Drug Profile 186 MK-7145 - Drug Profile 187 MP-3167 - Drug Profile 188 MPC-150IM - Drug Profile 189 MTP-131 - Drug Profile 191 MultiStem - Drug Profile 193 Mydicar - Drug Profile 196 MyoCell - Drug Profile 198 Neucardin - Drug Profile 199 NYK-1112 - Drug Profile 202 omecamtiv mecarbil - Drug Profile 203 ONO-4232 - Drug Profile 206 PB-1046 - Drug Profile 207 PGC Based Natriuretic Peptides - Drug Profile 209 PL-3994 - Drug Profile 210 poloxamer - Drug Profile 212 Protein for Diastolic Heart Failure - Drug Profile 214 pyroglutaminated serpinin - Drug Profile 215 QGC-101 - Drug Profile 216 REC-02 - Drug Profile 217 Recombinant Protein for Congestive Heart Failure - Drug Profile 218 rivaroxaban - Drug Profile 219 RNAi Gene Therapy to Inhibit STIM1 for Cardiovascular Diseases - Drug Profile 224 RNAi Oligonucleotide to Inhibit STIM1 for Cardiovascular Disorders - Drug Profile 226 S-38844 - Drug Profile 227 SAR-296968 - Drug Profile 228 serelaxin - Drug Profile 229 serpinin - Drug Profile 232 SG-1002 - Drug Profile 233 sildenafil citrate - Drug Profile 234 Small Molecule for Heart Failure-1 - Drug Profile 236 Small Molecule for Heart Failure-2 - Drug Profile 237 Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - Drug Profile 238 Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders - Drug Profile 239 Small Molecule to Inhibit NOX-4 for Heart Failure - Drug Profile 240 Small Molecules for Diabetes and Congestive Heart Failure - Drug Profile 241 Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile 242 Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile 243 Small Molecules to Inhibit G betagamma for Heart Failure, Hypertension, Inflammation and Pain - Drug Profile 244 Small Molecules to Inhibit PDE4 for Heart Failure - Drug Profile 245 Small Molecules to Inhibit PDE5 for Ischemia Reperfusion Injury - Drug Profile 246 Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Metabolic Syndrome and Heart Failure - Drug Profile 247 Small Molecules to Taregt Beta 2 Adrenergic Receptor and Cannabinoid Receptor for Oncology, Respiratory and Cardiovascular Disorders - Drug Profile 248 sodium nitrite - Drug Profile 249 SP-20202 - Drug Profile 251 Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 252 Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 254 Stem Cell Therapy for Chronic Heart Failure - Drug Profile 255 Stem Cell Therapy for Heart failure - Drug Profile 256 Stem Cell Therapy for Heart Failure - Drug Profile 257 TRC-4186 - Drug Profile 258 TRV-027 - Drug Profile 260 TRV-120023 - Drug Profile 262 udenafil - Drug Profile 263 ularitide - Drug Profile 265 vepoloxamer - Drug Profile 266 vericiguat - Drug Profile 267 XEN-105 - Drug Profile 268 Congestive Heart Failure (Heart Failure) - Recent Pipeline Updates 269 Congestive Heart Failure (Heart Failure) - Dormant Projects 343 Congestive Heart Failure (Heart Failure) - Discontinued Products 351 Congestive Heart Failure (Heart Failure) - Product Development Milestones 353 Featured News & Press Releases 353 Appendix 361 Methodology 361 Coverage 361 Secondary Research 361 Primary Research 361 Expert Panel Validation 361 Contact Us 361 Disclaimer 362
List of Tables Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2015 20 Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis, H1 2015 21 Number of Products under Development by Companies, H1 2015 23 Number of Products under Development by Companies, H1 2015 (Contd..1) 24 Number of Products under Development by Companies, H1 2015 (Contd..2) 25 Number of Products under Development by Companies, H1 2015 (Contd..3) 26 Number of Products under Development by Companies, H1 2015 (Contd..4) 27 Number of Products under Investigation by Universities/Institutes, H1 2015 29 Comparative Analysis by Late Stage Development, H1 2015 30 Comparative Analysis by Clinical Stage Development, H1 2015 31 Comparative Analysis by Early Stage Development, H1 2015 32 Products under Development by Companies, H1 2015 33 Products under Development by Companies, H1 2015 (Contd..1) 34 Products under Development by Companies, H1 2015 (Contd..2) 35 Products under Development by Companies, H1 2015 (Contd..3) 36 Products under Development by Companies, H1 2015 (Contd..4) 37 Products under Development by Companies, H1 2015 (Contd..5) 38 Products under Development by Companies, H1 2015 (Contd..6) 39 Products under Investigation by Universities/Institutes, H1 2015 40 Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 41 Congestive Heart Failure (Heart Failure) - Pipeline by Acorda Therapeutics, Inc., H1 2015 42 Congestive Heart Failure (Heart Failure) - Pipeline by Amgen Inc., H1 2015 43 Congestive Heart Failure (Heart Failure) - Pipeline by Anexon, Inc., H1 2015 44 Congestive Heart Failure (Heart Failure) - Pipeline by AnGes MG, Inc., H1 2015 45 Congestive Heart Failure (Heart Failure) - Pipeline by Angion Biomedica Corp., H1 2015 46 Congestive Heart Failure (Heart Failure) - Pipeline by ARCA biopharma, Inc., H1 2015 47 Congestive Heart Failure (Heart Failure) - Pipeline by Ascelegen Therapeutics, Inc., H1 2015 48 Congestive Heart Failure (Heart Failure) - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2015 49 Congestive Heart Failure (Heart Failure) - Pipeline by Athersys, Inc., H1 2015 50 Congestive Heart Failure (Heart Failure) - Pipeline by Bayer AG, H1 2015 51 Congestive Heart Failure (Heart Failure) - Pipeline by BEAT BioTherapeutics Corp., H1 2015 52 Congestive Heart Failure (Heart Failure) - Pipeline by Bial - Portela & Ca, S.A., H1 2015 53 Congestive Heart Failure (Heart Failure) - Pipeline by Bioheart, Inc., H1 2015 54 Congestive Heart Failure (Heart Failure) - Pipeline by BioLineRx, Ltd., H1 2015 55 Congestive Heart Failure (Heart Failure) - Pipeline by Bristol-Myers Squibb Company, H1 2015 56 Congestive Heart Failure (Heart Failure) - Pipeline by Cardio3 BioSciences SA, H1 2015 57 Congestive Heart Failure (Heart Failure) - Pipeline by Cardioxyl Pharmaceuticals, Inc., H1 2015 58 Congestive Heart Failure (Heart Failure) - Pipeline by Celladon Corporation, H1 2015 59 Congestive Heart Failure (Heart Failure) - Pipeline by Cellmid Limited, H1 2015 60 Congestive Heart Failure (Heart Failure) - Pipeline by FibroGen, Inc., H1 2015 61 Congestive Heart Failure (Heart Failure) - Pipeline by GlaxoSmithKline plc, H1 2015 62 Congestive Heart Failure (Heart Failure) - Pipeline by Glucox Biotech AB, H1 2015 63 Congestive Heart Failure (Heart Failure) - Pipeline by Innopharmax Inc., H1 2015 64 Congestive Heart Failure (Heart Failure) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 65 Congestive Heart Failure (Heart Failure) - Pipeline by Juventas Therapeutics, Inc., H1 2015 66 Congestive Heart Failure (Heart Failure) - Pipeline by Laboratoires Pierre Fabre SA, H1 2015 67 Congestive Heart Failure (Heart Failure) - Pipeline by Lead Pharma Holding B.V., H1 2015 68 Congestive Heart Failure (Heart Failure) - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 69 Congestive Heart Failure (Heart Failure) - Pipeline by Les Laboratoires Servier SAS, H1 2015 70 Congestive Heart Failure (Heart Failure) - Pipeline by Lonestar Heart, Inc., H1 2015 71 Congestive Heart Failure (Heart Failure) - Pipeline by Mast Therapeutics, Inc., H1 2015 72 Congestive Heart Failure (Heart Failure) - Pipeline by Merck & Co., Inc., H1 2015 73 Congestive Heart Failure (Heart Failure) - Pipeline by Mesoblast Limited, H1 2015 74 Congestive Heart Failure (Heart Failure) - Pipeline by Mezzion Pharma Co. Ltd., H1 2015 75 Congestive Heart Failure (Heart Failure) - Pipeline by MI.TO. Technology S.r.L., H1 2015 76 Congestive Heart Failure (Heart Failure) - Pipeline by miRagen Therapeutics, Inc., H1 2015 77 Congestive Heart Failure (Heart Failure) - Pipeline by NeoStem, Inc., H1 2015 78 Congestive Heart Failure (Heart Failure) - Pipeline by Novartis AG, H1 2015 79 Congestive Heart Failure (Heart Failure) - Pipeline by Nyken BV, H1 2015 80 Congestive Heart Failure (Heart Failure) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 81 Congestive Heart Failure (Heart Failure) - Pipeline by Palatin Technologies, Inc., H1 2015 82 Congestive Heart Failure (Heart Failure) - Pipeline by Pfizer Inc., H1 2015 83 Congestive Heart Failure (Heart Failure) - Pipeline by PharmaIN Corporation, H1 2015 84 Congestive Heart Failure (Heart Failure) - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2015 85 Congestive Heart Failure (Heart Failure) - Pipeline by Pluristem Therapeutics Inc., H1 2015 86 Congestive Heart Failure (Heart Failure) - Pipeline by QUANTUM GENOMICS Corp., H1 2015 87 Congestive Heart Failure (Heart Failure) - Pipeline by Recardio GmbH, H1 2015 88 Congestive Heart Failure (Heart Failure) - Pipeline by RedHill Biopharma Ltd., H1 2015 89 Congestive Heart Failure (Heart Failure) - Pipeline by RegenoCELL Therapeutics, Inc., H1 2015 90 Congestive Heart Failure (Heart Failure) - Pipeline by Sanofi, H1 2015 91 Congestive Heart Failure (Heart Failure) - Pipeline by Stemedica Cell Technologies, Inc., H1 2015 92 Congestive Heart Failure (Heart Failure) - Pipeline by Target Heart Biotec Srl, H1 2015 93 Congestive Heart Failure (Heart Failure) - Pipeline by Torrent Pharmaceuticals Limited, H1 2015 94 Congestive Heart Failure (Heart Failure) - Pipeline by Trevena, Inc., H1 2015 95 Congestive Heart Failure (Heart Failure) - Pipeline by uniQure N.V., H1 2015 96 Congestive Heart Failure (Heart Failure) - Pipeline by Vicore Pharma AB, H1 2015 97 Congestive Heart Failure (Heart Failure) - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2015 98 Assessment by Monotherapy Products, H1 2015 99 Assessment by Combination Products, H1 2015 100 Number of Products by Stage and Target, H1 2015 102 Number of Products by Stage and Mechanism of Action, H1 2015 106 Number of Products by Stage and Route of Administration, H1 2015 110 Number of Products by Stage and Molecule Type, H1 2015 112 Congestive Heart Failure (Heart Failure) Therapeutics - Recent Pipeline Updates, H1 2015 277 Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2015 351 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..1), H1 2015 352 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..2), H1 2015 353 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..3), H1 2015 354 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..4), H1 2015 355 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..5), H1 2015 356 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..6), H1 2015 357 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..7), H1 2015 358 Congestive Heart Failure (Heart Failure) - Discontinued Products, H1 2015 359 Congestive Heart Failure (Heart Failure) - Discontinued Products (Contd..1), H1 2015 360
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.